SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Metrics to compare | SCYX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSCYXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −2.8x | −0.5x | |
PEG Ratio | 0.01 | 0.01 | 0.00 | |
Price/Book | 0.5x | 2.1x | 2.6x | |
Price / LTM Sales | 10.4x | 1.4x | 3.2x | |
Upside (Analyst Target) | - | 168.8% | 42.0% | |
Fair Value Upside | Unlock | 16.3% | 6.6% | Unlock |